Nvwm LLC Has $30,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Nvwm LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 97.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 348 shares of the company’s stock after selling 11,447 shares during the quarter. Nvwm LLC’s holdings in Novo Nordisk A/S were worth $30,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Albion Financial Group UT lifted its stake in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC boosted its position in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $46,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $85.83 on Thursday. The business has a 50-day moving average of $92.65 and a 200-day moving average of $112.19. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a market capitalization of $385.16 billion, a price-to-earnings ratio of 27.78, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.